The first triple-receptor agonist, simultaneously activating GIP, GLP-1, and glucagon pathways for maximum weight loss. The third receptor —glucagon — is what sets it apart: it actively increases energy expenditure, boosts resting metabolic rate, and targets liver fat. In the Phase 2 trial (NEJM2023), patients on the 12 mg dose achieved 24.2% body weight reduction in 48 weeks, with 100% losing at least 5%. Sub-study analysis showed up to 86% liver fat reduction. Phase 3 data shows up to 28.7% at 68 weeks — surpassing both semaglutide and tirzepatide. Eat less, metabolize better, burn more — all from one weekly injection. Physician-prescribed, compounded by a licensed 503B pharmacy, HSA/FSA eligible, shipped to your door.
